Repealing the IMD Exclusion Act

HR 6727, the Repealing the IMD Exclusion Act, was introduced on December 15, 2025, by Rep. Ritchie Torres (D-NY-15) and referred to the House Energy and Commerce Committee. The bill removes the current law's exclusion of federal Medicaid payments for services provided in Institutions for Mental Diseases (IMDs) with more than 16 beds for patients under age 65. Instead, any institution primarily treating mental diseases would qualify if it meets nationally recognized, evidence-based standards (e.g., ASAM for SUDs). This is a regulatory change — it authorizes no direct spending but expands the reimbursement base. The money trail: this bill is an authorization that changes Medicaid's statutory exclusion. If passed, CMS would need to update regulations, and state Medicaid agencies would begin reimbursing for care in larger IMDs. No new appropriation is required because Medicaid is an entitlement; the federal matching funds automatically adjust to cover newly eligible services. The fiscal impact would be an increase in federal Medicaid outlays proportional to the additional patient volume, estimated in the billions over ten years (CBO score not yet available given early stage). Structural winners: $UHS (Universal Health Services) is the most direct beneficiary as the largest psychiatric hospital operator in the U.S., with behavioral health comprising a majority of its revenue. $ACAD (Acadia Pharmaceuticals) gains secondarily from higher inpatient volumes driving Nuplazid prescriptions. Other potential beneficiaries include medium-cap operators not yet named in the ticker list, but $UHS and $ACAD are the most exposed pure-plays. Real market data: $UHS has declined 5.81% over the past 30 days, closing at $168.57 on April 30, 2026, with a significant drop from $181.18 on April 23 to $162.54 on April 28 — this appears unrelated to HR 6727 (which had no new actions) and likely reflects broader market or sector-specific pressures. $ACAD is relatively stable at $22.47, up 2.32% over 7 days. Neither stock shows a catalyst from this early-stage bill. Timeline: the bill is at the earliest stage — referred to committee with no hearings scheduled. The 119th Congress runs through January 2027. Passage probability is low in its current form given divided government and the significant budget implications. Floor action is unlikely before 2027 unless bipartisan consensus emerges in committee.